Invitae (OTC: NVTA)
Invitae Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Invitae Company Info
Invitae offers medical genetics testing for a variety of diseases, disorders, and pediatric conditions.
News & Analysis
Is Invitae Stock a Buy Now?
Invitae shares have lost more than 80% over the past year and a half.
3 Things About Invitae Every Smart Investor Knows
The last two years have been tumultuous, and there are no calm waters in sight.
Is Invitae Stock a Buy Now?
Invitae shares have dropped more than 60% this year.
Why Invitae Stock Popped Today
Invitae just received a key marketing authorization from the FDA for a first-of-its-kind cancer test.
Invitae Stock Analysis: Buy, Sell, or Hold?
The genetic testing company is reducing costs to improve margins.
Cathie Wood Is Betting on This Struggling Stock. Should You?
The stock has lost 90% in about 18 months.
Why Invitae Stock Is Crashing Today
The bad news continues to pour in for this beaten-down genetic testing stock.
Down 96%, Is Invitae Stock a Buy?
The innovative medical services company is making adjustments to improve the bottom line.
Valuation
Earnings Transcripts
Invitae (NVTA) Q3 2023 Earnings Call Transcript
NVTA earnings call for the period ending September 30, 2023.
Invitae (NVTA) Q2 2023 Earnings Call Transcript
NVTA earnings call for the period ending June 30, 2023.
Invitae (NVTA) Q1 2023 Earnings Call Transcript
NVTA earnings call for the period ending March 31, 2023.
Invitae (NVTA) Q4 2022 Earnings Call Transcript
NVTA earnings call for the period ending December 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.